Pfizer has revealed plans to invest $465m for the construction of an advanced sterile injectable pharmaceutical manufacturing plant at Portage in Michigan, US.
The multi-storey, 400,000ft2 Modular Aseptic Processing (MAP) facility is intended to bolster the company’s production and supply capacity.
MAP will feature advanced aseptic manufacturing equipment, systems and design. It will be equipped with multiple, self-contained modular manufacturing lines.
Pfizer chairman and CEO Ian Read said: “This investment is part of our overall plan announced in January to invest approximately $5bn in US-based capital projects as a result of the enactment of the Tax Cuts and Jobs Act.
“Every day, we strive to enhance our ability to bring medicines to the patients who need them, and the new facility we are building in Michigan will help us continue to deliver therapies that significantly improve people’s lives.”
Over the next several years, the new production facility is expected to create approximately 450 jobs in Portage where the company currently employs over 2,200 people at another site.
Operational since 1948, the site primarily supplies more than 150 sterile injectable medicines, liquids and semi-solid therapeutics, as well as active pharmaceutical ingredients.
Pfizer Global Supply executive vice-president and president Kirsten Lund-Jurgensen said: “This investment will strengthen Pfizer’s leadership in sterile manufacturing technology and help meet growing patient demand.
“It also will create hundreds of highly skilled jobs, fortifying Michigan’s high-tech manufacturing environment.”
The company operates a total of 15 manufacturing and supply plants across the world. Its facilities in the US employ more than 11,000 staff.
Construction of the new US plant is set to begin next year and scheduled to be completed in 2021, with plans to commence production in 2024.